Charles Bennett to Drug Approval
This is a "connection" page, showing publications Charles Bennett has written about Drug Approval.
Connection Strength
4.582
-
Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions. Lancet Oncol. 2020 12; 21(12):e575-e588.
Score: 0.691
-
Challenges to Biosimilar Substitution. JAMA. 2017 09 26; 318(12):1186.
Score: 0.554
-
Federal 340B Program Payment Scheme for Drugs Designated As Orphan Products: Congressional Clarification Needed to Close the Government-Industry Revolving Door. J Clin Oncol. 2016 12 20; 34(36):4320-4322.
Score: 0.521
-
FDA Approval of Extended-Release Oxycodone for Children With Severe Pain. Pediatrics. 2016 05; 137(5).
Score: 0.502
-
Japanese regulatory authority's perspective on biosimilars - authors' reply. Lancet Oncol. 2015 Mar; 16(3):e102.
Score: 0.464
-
Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol. 2014 Dec; 15(13):e594-e605.
Score: 0.455
-
Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? J Clin Oncol. 2009 Sep 10; 27(26):4398-405.
Score: 0.315
-
Single-arm clinical trials that supported FDA accelerated approvals have modest effect sizes and were at high risk of bias. J Clin Epidemiol. 2022 08; 148:193-195.
Score: 0.187
-
Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre-ibrutinib era: Incidence and risk factors. Cancer Med. 2019 05; 8(5):2233-2240.
Score: 0.154
-
Biosimilar Filgrastim Use in the United States vs the European Union and Japan-Why Does It Lag Behind and What Can Be Done? JAMA Oncol. 2019 03 01; 5(3):297-298.
Score: 0.153
-
Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition. Drugs. 2018 Nov; 78(17):1777-1781.
Score: 0.150
-
Interpretation of surrogate endpoints in the era of the 21st Century Cures Act. BMJ. 2016 Dec 30; 355:i6286.
Score: 0.132
-
A tale of two citizens: a State Attorney General and a hematologist facilitate translation of research into US Food and Drug Administration actions--a SONAR report. J Oncol Pract. 2012 Nov; 8(6):e158-67.
Score: 0.097
-
Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol. 2008 Dec; 9(12):1166-72.
Score: 0.075
-
Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. J Clin Oncol. 2003 Oct 15; 21(20):3859-66.
Score: 0.053
-
Medicare Spending on Drugs With Accelerated Approval. Ann Intern Med. 2022 07; 175(7):938-944.
Score: 0.048
-
Peginesatide for the treatment of anemia due to chronic kidney disease - an unfulfilled promise. Expert Opin Drug Saf. 2016 Oct; 15(10):1421-6.
Score: 0.032